

CITATION REPORT

List of articles citing

Vemurafenib significantly decreases glomerular filtration rate

DOI: 10.1111/jdv.12322

Journal of the European Academy of Dermatology and Venereology, 2014, 28, 978-9.

Source: <https://exaly.com/paper-pdf/58220439/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Renal Toxicities of Targeted Therapies. <i>Targeted Oncology</i> , 2015 , 10, 487-99	5	43
19	Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. <i>PLoS ONE</i> , 2016 , 11, e0149873	3.7	16
18	New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 419-26	3.5	21
17	BRAF inhibitors - do we need to worry about kidney injury?. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 579-81	4.1	7
16	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2016 , 9, 245-51	4.5	50
15	Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. <i>Targeted Oncology</i> , 2016 , 11, 59-69	5	33
14	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 176-189	6.9	28
13	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. <i>Kidney International Reports</i> , 2017 , 2, 108-123	4.1	42
12	Chronic Kidney Disease as a Complication of Cancer. <i>Journal of Onco-Nephrology</i> , 2017 , 1, 74-80	0.2	2
11	[Monitoring of hypertension in patients orally treated by angiogenesis inhibitor in daily practice]. <i>Nephrologie Et Therapeutique</i> , 2018 , 14, 99-104	0.6	0
10	MAP3K kinases and kidney injury. <i>Nefrologia</i> , 2019 , 39, 568-580	1.5	10
9	MAP3K kinases and kidney injury. <i>Nefrologia</i> , 2019 , 39, 568-580	0.4	3
8	Hyponatremia and MAP-kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 326-331	4.5	5
7	[Renal toxicities of targeted therapies in oncology]. <i>Nephrologie Et Therapeutique</i> , 2020 , 16, 1-8	0.6	0
6	Nephrotoxic Chemotherapy Agents: Old and New. <i>Advances in Chronic Kidney Disease</i> , 2020 , 27, 38-49	4.7	5
5	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. <i>Anti-Cancer Drugs</i> , 2021 , 32, 1076-1083	2.4	1
4	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. <i>Kidney International</i> , 2021 , 100, 1214-1226	9.9	2

3	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021 , 40, 344-354	3.6	2
2	Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibition.		1
1	[Renal toxicity of anticancer drugs]. <i>Nephrologie Et Therapeutique</i> , 2021 , 17, 553-563	0.6	1